Bio-Techne (TECH) Non Operating Investment Income (2014 - 2023)

Bio-Techne's (TECH) quarterly Non Operating Investment Income came in at $283000.0 in Q3 2023, down 99.43% year-on-year from $49.8 million in Q3 2022, and up 141.56% quarter-over-quarter from -$681000.0 in Q2 2023.

Bio-Techne (TECH) Non Operating Investment Income (2014 - 2023) Analysis & Trends

Bio-Techne's Non Operating Investment Income history runs 3 years deep, the most recent figure standing at $283000.0 for Q3 2023.

  • On a quarterly basis, Non Operating Investment Income fell 99.43% year-over-year to $283000.0 in Q3 2023; TTM through Jun 2024 was $283000.0, a 99.43% decrease from a year earlier, with the FY2024 full-year figure at $283000.0, down 99.43% from the prior year.
  • Non Operating Investment Income grew to $283000.0 in Q3 2023 per TECH's latest filing, from -$681000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $49.8 million in Q3 2022 and bottomed at -$681000.0 in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Bio-Techne 11.23 Bn 11.02 Bn 208.29 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2023 283,000.00
Sep 30, 2023 283,000.00
Jun 30, 2023 -681,000.00
Jun 30, 2023 -681,000.00
Mar 31, 2023 314,000.00
Mar 31, 2023 314,000.00
Dec 31, 2022 -74,000.00
Dec 31, 2022 -74,000.00
Sep 30, 2022 49.77 Mn
Sep 30, 2022 49.77 Mn
Dec 31, 2014 8.30 Mn
Dec 31, 2014 8.30 Mn